Details of the Drug

General Information of Drug (ID: DMDL27I)

Drug Name
Oxytocin
Synonyms
OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior; Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat)
Indication
Disease Entry ICD 11 Status REF
Autism spectrum disorder 6A02 Approved [1]
Lactation failure JB46.3 Phase 3 [2]
Drug Type
Recombinant hormone
Sequence
CYIQNCPLG
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1007.2
Topological Polar Surface Area (xlogp) -2.6
Rotatable Bond Count (rotbonds) 17
Hydrogen Bond Donor Count (hbonddonor) 12
Hydrogen Bond Acceptor Count (hbondacc) 15
Chemical Identifiers
Formula
C43H66N12O12S2
IUPAC Name
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
Canonical SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
InChI
InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
InChIKey
XNOPRXBHLZRZKH-DSZYJQQASA-N
Cross-matching ID
PubChem CID
439302
ChEBI ID
CHEBI:7872
CAS Number
50-56-6
DrugBank ID
DB00107
TTD ID
D0M3FJ
VARIDT ID
DR01199
ACDINA ID
D01310

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Modulator [3], [4]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Agonist [5]
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Agonist [6]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Agonist [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Autism spectrum disorder
ICD Disease Classification 6A02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vasopressin V1b receptor (V1BR) DTT AVPR1B 5.14E-01 -0.03 -0.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxytocin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Oxytocin and Ivosidenib. Acute myeloid leukaemia [2A60] [33]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Midostaurin. Acute myeloid leukaemia [2A60] [34]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Idarubicin. Acute myeloid leukaemia [2A60] [34]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Daunorubicin. Acute myeloid leukaemia [2A60] [34]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Arn-509. Acute myeloid leukaemia [2A60] [35]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Gilteritinib. Acute myeloid leukaemia [2A60] [36]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [34]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Tacrine. Alzheimer disease [8A20] [34]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Galantamine. Alzheimer disease [8A20] [34]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Rivastigmine. Alzheimer disease [8A20] [34]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Donepezil. Alzheimer disease [8A20] [34]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Oxytocin and Metronidazole. Amoebiasis [1A36] [37]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ranolazine. Angina pectoris [BA40] [38]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Oxytocin and Ivabradine. Angina pectoris [BA40] [35]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Oxytocin and Bepridil. Angina pectoris [BA40] [34]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Oxytocin and Dronedarone. Angina pectoris [BA40] [34]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Oxytocin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [39]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [34]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Promazine. Appearance/behaviour symptom [MB23] [34]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Cilostazol. Arterial occlusive disease [BD40] [34]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Voriconazole. Aspergillosis [1F20] [34]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Posaconazole. Aspergillosis [1F20] [34]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Levalbuterol. Asthma [CA23] [40]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Terbutaline. Asthma [CA23] [41]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Pirbuterol. Asthma [CA23] [41]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Isoetharine. Asthma [CA23] [41]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Salbutamol. Asthma [CA23] [40]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Formoterol. Asthma [CA23] [41]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [35]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Desipramine. Attention deficit hyperactivity disorder [6A05] [34]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [34]
Erythromycin DM4K7GQ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Erythromycin. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Clarithromycin. Bacterial infection [1A00-1C4Z] [34]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Oxytocin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [34]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Oxytocin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Levofloxacin. Bacterial infection [1A00-1C4Z] [42]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Oxytocin and Moxifloxacin. Bacterial infection [1A00-1C4Z] [43]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [34]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Telithromycin. Bacterial infection [1A00-1C4Z] [34]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Retigabine. Behcet disease [4A62] [34]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Loperamide. Bowel habit change [ME05] [44]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Eribulin. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lapatinib. Breast cancer [2C60-2C6Y] [34]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Tamoxifen. Breast cancer [2C60-2C6Y] [34]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Oxytocin and Toremifene. Breast cancer [2C60-2C6Y] [34]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Bosutinib. Breast cancer [2C60-2C6Y] [35]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Oxytocin and Grepafloxacin. Bronchitis [CA20] [42]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Oxytocin and Sotalol. Cardiac arrhythmia [BC9Z] [34]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Oxytocin and Dofetilide. Cardiac arrhythmia [BC9Z] [34]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [45]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [41]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [40]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [41]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [41]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [41]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Oxaliplatin. Colorectal cancer [2B91] [34]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Atracurium. Corneal disease [9A76-9A78] [46]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Mivacurium. Corneal disease [9A76-9A78] [46]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Halothane. Corneal disease [9A76-9A78] [34]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Pancuronium. Corneal disease [9A76-9A78] [46]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Propofol. Corneal disease [9A76-9A78] [47]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Sevoflurane. Corneal disease [9A76-9A78] [34]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Probucol. Coronary atherosclerosis [BA80] [34]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Oxytocin and Methadone. Cough [MD12] [34]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Clofazimine. Crohn disease [DD70] [48]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Oxytocin and Mifepristone. Cushing syndrome [5A70] [34]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Oxytocin and Pasireotide. Cushing syndrome [5A70] [34]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Osilodrostat. Cushing syndrome [5A70] [35]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Sertraline. Depression [6A70-6A7Z] [34]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Trimipramine. Depression [6A70-6A7Z] [34]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Imipramine. Depression [6A70-6A7Z] [34]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Fluoxetine. Depression [6A70-6A7Z] [34]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Nortriptyline. Depression [6A70-6A7Z] [34]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Oxytocin and Escitalopram. Depression [6A70-6A7Z] [34]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Clomipramine. Depression [6A70-6A7Z] [34]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Trazodone. Depression [6A70-6A7Z] [49]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Amitriptyline. Depression [6A70-6A7Z] [34]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Amoxapine. Depression [6A70-6A7Z] [34]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Mirtazapine. Depression [6A70-6A7Z] [50]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Protriptyline. Depression [6A70-6A7Z] [34]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Doxepin. Depression [6A70-6A7Z] [34]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Maprotiline. Depression [6A70-6A7Z] [34]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Venlafaxine. Depression [6A70-6A7Z] [34]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Oxytocin and Citalopram derivative 1. Discovery agent [N.A.] [34]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [34]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Deutetrabenazine. Dystonic disorder [8A02] [51]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ingrezza. Dystonic disorder [8A02] [52]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Solifenacin. Functional bladder disorder [GC50] [34]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Pentamidine. Fungal infection [1F29-1F2F] [34]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Fluconazole. Fungal infection [1F29-1F2F] [34]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ketoconazole. Fungal infection [1F29-1F2F] [34]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Oxytocin and Cisapride. Gastro-oesophageal reflux disease [DA22] [34]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [34]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [53]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Oxytocin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [54]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Oxytocin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [55]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [34]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [34]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Polyethylene glycol. Irritable bowel syndrome [DD91] [35]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Phenolphthalein. Irritable bowel syndrome [DD91] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Oxytocin and Crizotinib. Lung cancer [2C25] [56]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Oxytocin and Ceritinib. Lung cancer [2C25] [34]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Oxytocin and Osimertinib. Lung cancer [2C25] [57]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Oxytocin and Selpercatinib. Lung cancer [2C25] [35]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Oxytocin and Lumefantrine. Malaria [1F40-1F45] [37]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Oxytocin and Halofantrine. Malaria [1F40-1F45] [58]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Oxytocin and Chloroquine. Malaria [1F40-1F45] [59]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Oxytocin and Hydroxychloroquine. Malaria [1F40-1F45] [59]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Primaquine. Malaria [1F40-1F45] [34]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [35]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Oxytocin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [60]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Oxytocin and Vemurafenib. Melanoma [2C30] [34]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and LGX818. Melanoma [2C30] [61]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Oxytocin and Panobinostat. Multiple myeloma [2A83] [62]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Thalidomide. Multiple myeloma [2A83] [37]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Oxytocin and Siponimod. Multiple sclerosis [8A40] [37]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Oxytocin and Fingolimod. Multiple sclerosis [8A40] [34]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Oxytocin and Ozanimod. Multiple sclerosis [8A40] [63]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Romidepsin. Mycosis fungoides [2B01] [34]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Oxytocin and Nilotinib. Myeloproliferative neoplasm [2A20] [34]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Dasatinib. Myeloproliferative neoplasm [2A20] [64]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Oxytocin and Droperidol. Nausea/vomiting [MD90] [34]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Prochlorperazine. Nausea/vomiting [MD90] [34]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Promethazine. Nausea/vomiting [MD90] [34]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Palonosetron. Nausea/vomiting [MD90] [34]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Granisetron. Nausea/vomiting [MD90] [34]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Oxytocin and Dolasetron. Nausea/vomiting [MD90] [34]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Ondansetron. Nausea/vomiting [MD90] [34]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Entrectinib. Non-small cell lung cancer [2C25] [37]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Oxytocin and Levomethadyl Acetate. Opioid use disorder [6C43] [35]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lofexidine. Opioid use disorder [6C43] [34]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Rucaparib. Ovarian cancer [2C73] [34]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Dextropropoxyphene. Pain [MG30-MG3Z] [65]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Buprenorphine. Pain [MG30-MG3Z] [34]
Tramadol DMRQD04 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Tramadol. Pain [MG30-MG3Z] [34]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Triclabendazole. Parasitic worm infestation [1F90] [34]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Pimavanserin. Parkinsonism [8A00] [66]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Apomorphine. Parkinsonism [8A00] [34]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Famotidine. Peptic ulcer [DA61] [37]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Oxytocin and Macimorelin. Pituitary gland disorder [5A60-5A61] [67]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Oxytocin and Lefamulin. Pneumonia [CA40] [68]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Ritodrine. Preterm labour/delivery [JB00] [41]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Degarelix. Prostate cancer [2C82] [35]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Oxytocin and ABIRATERONE. Prostate cancer [2C82] [35]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Nilutamide. Prostate cancer [2C82] [35]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Enzalutamide. Prostate cancer [2C82] [35]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Flutamide. Prostate cancer [2C82] [35]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Relugolix. Prostate cancer [2C82] [35]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Bicalutamide. Prostate cancer [2C82] [35]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Alfuzosin. Prostate hyperplasia [GA90] [34]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Levomepromazine. Psychotic disorder [6A20-6A25] [34]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Fluphenazine. Psychotic disorder [6A20-6A25] [34]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Triflupromazine. Psychotic disorder [6A20-6A25] [34]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Sorafenib. Renal cell carcinoma [2C90] [34]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Oxytocin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [43]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Quetiapine. Schizophrenia [6A20] [34]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Oxytocin and Mesoridazine. Schizophrenia [6A20] [34]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Oxytocin and Thioridazine. Schizophrenia [6A20] [34]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Aripiprazole. Schizophrenia [6A20] [37]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Oxytocin and Iloperidone. Schizophrenia [6A20] [34]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Paliperidone. Schizophrenia [6A20] [34]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Oxytocin and Haloperidol. Schizophrenia [6A20] [34]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Perphenazine. Schizophrenia [6A20] [34]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Chlorpromazine. Schizophrenia [6A20] [34]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Oxytocin and Clozapine. Schizophrenia [6A20] [34]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Trifluoperazine. Schizophrenia [6A20] [34]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Oxytocin and Ziprasidone. Schizophrenia [6A20] [34]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Risperidone. Schizophrenia [6A20] [34]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Oxytocin and Amisulpride. Schizophrenia [6A20] [69]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Asenapine. Schizophrenia [6A20] [34]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Oxytocin and Pimozide. Schizophrenia [6A20] [35]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Vardenafil. Sexual dysfunction [HA00-HA01] [34]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [34]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Oxytocin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [34]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [35]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [34]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Pitolisant. Somnolence [MG42] [34]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [34]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Oxytocin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [34]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Oxytocin and Adenosine. Supraventricular tachyarrhythmia [BC81] [34]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Zithromax. Syphilis [1A61-1A6Z] [34]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Oxytocin and Anagrelide. Thrombocytosis [3B63] [34]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Lenvatinib. Thyroid cancer [2D10] [34]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Oxytocin and Cabozantinib. Thyroid cancer [2D10] [35]
Succinylcholine DM2ET1M Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Succinylcholine. Tonus and reflex abnormality [MB47] [46]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Oxytocin and Papaverine. Tonus and reflex abnormality [MB47] [70]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Vecuronium. Tonus and reflex abnormality [MB47] [46]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Tizanidine. Tonus and reflex abnormality [MB47] [34]
Cisatracurium DMUZPJ5 Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Cisatracurium. Tonus and reflex abnormality [MB47] [46]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Oxytocin and Rocuronium. Tonus and reflex abnormality [MB47] [46]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Tacrolimus. Transplant rejection [NE84] [34]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Astemizole. Vasomotor/allergic rhinitis [CA08] [34]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Oxytocin and Disopyramide. Ventricular tachyarrhythmia [BC71] [34]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Oxytocin and Procainamide. Ventricular tachyarrhythmia [BC71] [34]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Propafenone. Ventricular tachyarrhythmia [BC71] [34]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Oxytocin and Flecainide. Ventricular tachyarrhythmia [BC71] [34]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Oxytocin and Amiodarone. Ventricular tachyarrhythmia [BC71] [34]
⏷ Show the Full List of 200 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acetic acid E00002 176 Acidulant; Buffering agent
Anhydrous chlorobutanol E00089 5977 Antimicrobial preservative; Plasticizing agent
Chlorobutanol hemihydrate E00476 5284505 Antimicrobial preservative; Plasticizing agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Oxytocin 10usp units/ml injectable 10usp units/ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
4 Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science. 1982 Mar 12;215(4538):1396-8.
5 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
6 The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
8 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
9 New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
10 The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
11 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
12 The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
13 Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
14 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
15 Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
16 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
17 Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
18 Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
19 Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
20 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
22 Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
23 Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
24 Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
25 Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
26 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
27 Clinical pipeline report, company report or official report of Avarx.
28 Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
29 The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
30 The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
31 Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
32 A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
33 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
34 Canadian Pharmacists Association.
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
37 Cerner Multum, Inc. "Australian Product Information.".
38 European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
39 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
40 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
41 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
42 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
43 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
44 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
45 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46 Multum Information Services, Inc. Expert Review Panel.
47 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
48 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
49 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
50 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
51 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
52 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
53 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
54 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
55 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
56 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
59 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
60 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
61 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
62 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
64 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
65 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
66 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
67 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
68 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
70 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]